Hepatitis Community Educators with AbbVie
Tag Archive for: Pharmaceutical
A network building capacity to prevent, manage and treat hepatitis B and C in NYC
Kadmon Corporation KEYS Program Kadmon Enabling Your Success $5 Co-Pay card for RibaPak Visit us online
Gilead R&D has helped transform the treatment of chronic hepatitis C infection and help manage chronic hepatitis B infection.
To discover, develop and deliver innovative medicines that help patients prevail over serious diseases. To our patients and customers, employees, global communities, shareholders, environment and other stakeholders, we promise to act on our belief that the priceless ingredient of...
The FDA has approved the drug Epclusa to treat adult patients with chronic Hep C both with and without cirrhosis.
FDA Approves Daklinza/Sovaldi to Treat Hep C Genotype 1
News, Hepatitis C, HepCX News, PharmaceuticalFDA Expands Daklinza/Sovaldi Approval to Include Treatment of Hep C Genotype 1
The U.S. Food and Drug Administration has approved Zepatier with or without ribavirin for the treatment of chronic Hepatitis C genotypes 1 and 4 infections in adult patients.
FDA Approves Revisions to the Olysio (Simeprevir) Label, Including Dosing Recommendations
News, HepCX News, PharmaceuticalDA approved revisions to the Olysio (simeprevir) label to include dosing recommendations for the treatment of HCV/HIV-1 coinfection and to expand the indications and usage to include genotype 4 infection.
NYS DOH Approves Viekira Pak as Preferred Drug for Hep C for FFS Medicaid Beneficiaries
News, HepCX News, Medicaid, PharmaceuticalYSDOH Drug Utilization Review Board meeting, the board voted to approve Viekira Pak as its preferred drug for persons chronically infected with HCV and enrolled in FFS Medicaid. Viekira Pak will be available for all chronically infected persons regardless of disease severity. Thi...
Viekira Pak now preferred under NYS Medicaid Fee For Service (FFS)
News, HepCX News, Medicaid, PharmaceuticalOn Feb 26th, 2015, the NYS Drug Utilization Review Board (DURB) voted unanimously to move Viekira Pak to preferred status for NYS Medicaid Fee-for-service members, and to remove restrictions based on disease prognosis and severity from the current clinical criteria for Viekira Pa...
Upcoming Events
International Women’s Day
Hep C & Drug User Health: Hep C Reinfection (Clinical Education Initiative)
CDC’s Harm Reduction Technical Assistance Program for SSPs
News & Recent Posts
- Internship | PT Peer RADx-UP Program @ Alliance Lower East Side Harm Reduction Center March 4, 2021
- NYC Health Department Form to Self-Certify Medical Condition for COVID-19 Vaccine Eligibility (including Liver Disease) February 23, 2021
- Coalition against Hepatitis in People of African Origin (CHIPO) NYC February 17, 2021
- Job | Certified Recovery Peer Advocate @ Addiction Care Interventions February 12, 2021
- Job | Partnerships & Communications Associate Director @ Stanford University Asian Liver Center February 11, 2021
- CHIPO-NYC Committee Meeting Highlights | 1-27-21 February 4, 2021